The Enigma of Tau Protein Aggregation: Mechanistic Insights and Future Challenges

Tau protein misfolding and aggregation are pathological hallmarks of Alzheimer’s disease and over twenty neurodegenerative disorders. However, the molecular mechanisms of tau aggregation in vivo remain incompletely understood. There are two types of tau aggregates in the brain: soluble aggregates (oligomers and protofibrils) and insoluble filaments (fibrils). Compared to filamentous aggregates, soluble aggregates are more toxic and exhibit prion-like transmission, providing seeds for templated misfolding. Curiously, in its native state, tau is a highly soluble, heat-stable protein that does not form fibrils by itself, not even when hyperphosphorylated. In vitro studies have found that negatively charged molecules such as heparin, RNA, or arachidonic acid are generally required to induce tau aggregation. Two recent breakthroughs have provided new insights into tau aggregation mechanisms. First, as an intrinsically disordered protein, tau is found to undergo liquid-liquid phase separation (LLPS) both in vitro and inside cells. Second, cryo-electron microscopy has revealed diverse fibrillar tau conformations associated with different neurodegenerative disorders. Nonetheless, only the fibrillar core is structurally resolved, and the remainder of the protein appears as a “fuzzy coat”. From this review, it appears that further studies are required (1) to clarify the role of LLPS in tau aggregation; (2) to unveil the structural features of soluble tau aggregates; (3) to understand the involvement of fuzzy coat regions in oligomer and fibril formation.

• Publication year

  2024

• Venue

  International Journal of Molecular Sciences

• Publication date

  2024-05-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.3390/ijms25094969PMID 38732197PMCID 11084794
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Evidence for trans-synaptic propagation of oligomeric tau in human progressive supranuclear palsy

  2025cited by this paper
• Disentangling tau: One protein, many therapeutic approaches

  2024cited by this paper
• Liquid–liquid phase separation in Alzheimer’s disease

  2024cited by this paper
• Tau filaments are tethered within brain extracellular vesicles in Alzheimer’s disease

  2024cited by this paper
• Frontotemporal lobar degeneration

  2023cited by this paper
• Limitations of human tau-expressing mouse models and novel approaches of mouse modeling for tauopathy

  2023cited by this paper
• Tau filaments are tethered within brain extracellular vesicles in Alzheimer’s disease

  2023cited by this paper
• Disease-specific tau filaments assemble via polymorphic intermediates

  2023cited by this paper
• The Role of Tau Proteoforms in Health and Disease

  2023cited by this paper
• IP-LC-MSMS Enables Identification of Three Tau O-GlcNAcylation Sites as O-GlcNAcase Inhibition Pharmacodynamic Readout in Transgenic Mice Overexpressing Human Tau.

  2023cited by this paper
• Travels with tau prions

  2023cited by this paper
• Tau seeds from Alzheimer's disease brains trigger tau spread in macaques while oligomeric‐Aβ mediates pathology maturation

  2023cited by this paper
• Liquid - liquid phase separation of tau: Driving forces, regulation, and biological implications.

  2023cited by this paper
• Tau seeding and spreading in vivo is supported by both AD-derived fibrillar and oligomeric tau

  2023cited by this paper
• Tau Filaments from Amyotrophic Lateral Sclerosis/Parkinsonism-Dementia Complex (ALS/PDC) adopt the CTE Fold

  2023cited by this paper
• Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer’s Disease

  2023cited by this paper
• Fully co-factor-free ClearTau platform produces seeding-competent Tau fibrils for reconstructing pathological Tau aggregates

  2023cited by this paper
• Identical tau filaments in subacute sclerosing panencephalitis and chronic traumatic encephalopathy

  2023cited by this paper
• Heterotypic liquid-liquid phase separation of tau and α-synuclein: Implications for overlapping neuropathologies.

  2023cited by this paper
• Molecular pathology of neurodegenerative diseases by cryo-EM of amyloids

  2023cited by this paper
• Tau-targeting therapies for Alzheimer disease: current status and future directions

  2023cited by this paper
• Synaptic oligomeric tau in Alzheimer's disease - a potential culprit in the spread of tau pathology through the brain

  2023cited by this paper
• Alzheimer's disease drug development pipeline: 2023

  2023cited by this paper
• Blood-based biomarkers for Alzheimer's disease: Current state and future use in a transformed global healthcare landscape.

  2023cited by this paper
• Big Tau: What We Know, and We Need to Know

  2023cited by this paper
• Emerging trends in cryo-EM-based structural studies of neuropathological amyloids.

  2023cited by this paper
• Self‐Aggregating Tau Fragments Recapitulate Pathologic Phenotypes and Neurotoxicity of Alzheimer's Disease in Mice

  2023cited by this paper
• An anti-amyloid therapy works for Alzheimer’s disease: why has it taken so long and what is next?

  2023cited by this paper
• Amyloid Aggregation and Liquid-Liquid Phase Separation from the Perspective of Phase Transitions.

  2023cited by this paper
• Evaluation of Tau Radiotracers in Chronic Traumatic Encephalopathy

  2022cited by this paper
• Liquid-Liquid Phase Separation of TDP-43 and FUS in Physiology and Pathology of Neurodegenerative Diseases

  2022cited by this paper
• Lecanemab, Aducanumab, and Gantenerumab — Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer’s Disease

  2022cited by this paper
• Passive Immunotherapy Targeting Tau Oligomeric Strains Reverses Tauopathy Phenotypes in Aged Human-Tau Mice in a Mouse Model-Specific Manner

  2022cited by this paper
• Seed-competent tau monomer initiates pathology in a tauopathy mouse model

  2022cited by this paper
• Classification of diseases with accumulation of Tau protein

  2022cited by this paper
• Quantifying Oligomer Populations in Real Time during Protein Aggregation Using Single-Molecule Mass Photometry

  2022cited by this paper
• All the Tau We Cannot See

  2022cited by this paper
• Microtubule-binding core of the tau protein

  2022cited by this paper
• Tau liquid-liquid phase separation in neurodegenerative diseases.

  2022cited by this paper
• The prion-like transmission of tau oligomers via exosomes

  2022cited by this paper
• On the role of phase separation in the biogenesis of membraneless compartments

  2022cited by this paper
• The tau oligomer antibody APNmAb005 detects early-stage pathological tau enriched at synapses and rescues neuronal loss in long-term treatments

  2022cited by this paper
• Expanded Conformations of Monomeric Tau Initiate Its Amyloidogenesis.

  2022cited by this paper
• Tau Toxicity in Neurodegeneration

  2022cited by this paper
• Hyperphosphorylated tau self-assembles into amorphous aggregates eliciting TLR4-dependent responses

  2022cited by this paper
• Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019

  2022cited by this paper
• Amyloid and Tau Positron Emission Tomography Imaging in Alzheimer’s Disease and Other Tauopathies

  2022cited by this paper
• Subtle change of fibrillation condition leads to substantial alteration of recombinant Tau fibril structure

  2022cited by this paper
• Cellular and pathological heterogeneity of primary tauopathies

  2021cited by this paper
• The 'a, b, c's of pretangle tau and their relation to aging and the risk of Alzheimer's Disease.

  2021cited by this paper
• Tau: A Signaling Hub Protein

  2021cited by this paper
• Liquid–liquid phase separation of Tau by self and complex coacervation

  2021cited by this paper
• Tau forms oligomeric complexes on microtubules that are distinct from tau aggregates

  2021cited by this paper
• Liquid–liquid phase separation in human health and diseases

  2021cited by this paper
• Visualization of neurofibrillary tangle maturity in Alzheimer's disease: A clinicopathologic perspective for biomarker research

  2021cited by this paper
• How do protein domains of low sequence complexity work?

  2021cited by this paper
• In vivo rate-determining steps of tau seed accumulation in Alzheimer’s disease

  2021cited by this paper
• The Sulfation Code of Tauopathies: Heparan Sulfate Proteoglycans in the Prion Like Spread of Tau Pathology

  2021cited by this paper
• p62-containing, proteolytically active nuclear condensates, increase the efficiency of the ubiquitin–proteasome system

  2021cited by this paper
• Pathologic tau conformer ensembles induce dynamic, liquid-liquid phase separation events at the nuclear envelope

  2021cited by this paper
• Differential Effects of the Six Human TAU Isoforms: Somatic Retention of 2N-TAU and Increased Microtubule Number Induced by 4R-TAU

  2021cited by this paper
• Neurodegenerative

  2021cited by this paper
• Amyloid Oligomers: A Joint Experimental/Computational Perspective on Alzheimer's Disease, Parkinson's Disease, Type II Diabetes, and Amyotrophic Lateral Sclerosis.

  2021cited by this paper
• A critical appraisal of tau‐targeting therapies for primary and secondary tauopathies

  2021cited by this paper
• Targeting tau only extracellularly is likely to be less efficacious than targeting it both intra- and extracellularly.

  2021cited by this paper
• Current Status of Clinical Trials on Tau Immunotherapies

  2021cited by this paper
• Structure of Tau filaments in Prion protein amyloidoses

  2021cited by this paper
• Tau Post-translational Modifications: Dynamic Transformers of Tau Function, Degradation, and Aggregation

  2021cited by this paper
• Exosomal and vesicle‐free tau seeds—propagation and convergence in endolysosomal permeabilization

  2021cited by this paper
• Alzheimer’s disease brain contains tau fractions with differential prion-like activities

  2021cited by this paper
• Blood‐based biomarkers for Alzheimer's disease

  2021cited by this paper
• Assembly of recombinant tau into filaments identical to those of Alzheimer’s disease and chronic traumatic encephalopathy

  2021cited by this paper
• Tau N-Terminal Inserts Regulate Tau Liquid-Liquid Phase Separation and Condensates Maturation in a Neuronal Cell Model

  2021cited by this paper
• TIA1 potentiates tau phase separation and promotes generation of toxic oligomeric tau

  2021cited by this paper
• IUPred3: prediction of protein disorder enhanced with unambiguous experimental annotation and visualization of evolutionary conservation

  2021cited by this paper
• Structure-based classification of tauopathies

  2021influential reference
• Tau Is Truncated in Five Regions of the Normal Adult Human Brain

  2021cited by this paper
• The role of pathological tau in synaptic dysfunction in Alzheimer’s diseases

  2021cited by this paper
• Tau Oligomers Neurotoxicity

  2021cited by this paper
• Targeted proteolytic products of τ and α-synuclein in neurodegeneration

  2021cited by this paper
• Amyloid-type Protein Aggregation and Prion-like Properties of Amyloids.

  2021cited by this paper
• Biomolecular condensates at the nexus of cellular stress, protein aggregation disease and ageing

  2021cited by this paper
• A current view on Tau protein phosphorylation in Alzheimer's disease.

  2021cited by this paper
• Past, present and future of therapeutic strategies against amyloid-β peptides in Alzheimer's disease a systematic review.

  2021cited by this paper
• Comorbid neuropathological diagnoses in early versus late-onset Alzheimer's disease.

  2021cited by this paper
• The multiplex model of the genetics of Alzheimer’s disease

  2020cited by this paper
• Internalization mechanisms of brain-derived tau oligomers from patients with Alzheimer’s disease, progressive supranuclear palsy and dementia with Lewy bodies

  2020cited by this paper
• Regulatory mechanisms of tau protein fibrillation under the conditions of liquid–liquid phase separation

  2020cited by this paper
• The glassiness of hardening protein droplets

  2020cited by this paper
• Biomolecular Phase Separation: From Molecular Driving Forces to Macroscopic Properties.

  2020cited by this paper
• Liquid-liquid phase separation of tau driven by hydrophobic interaction facilitates fibrillization of tau

  2020influential reference
• Prion-like properties of Tau assemblies.

  2020cited by this paper
• The proline-rich domain promotes Tau liquid–liquid phase separation in cells

  2020cited by this paper
• Characterization and validation of 16 α-synuclein conformation-specific antibodies using well-characterized preparations of α-synuclein monomers, fibrils and oligomers with distinct structures and morphology: How specific are the conformation-specific α-synuclein antibodies?

  2020cited by this paper
• Novel tau filament fold in corticobasal degeneration

  2020cited by this paper
• Much More Than a Cytoskeletal Protein: Physiological and Pathological Functions of the Non-microtubule Binding Region of Tau

  2020cited by this paper
• Electrostatically driven complex coacervation and amyloid aggregation of tau are independent processes with overlapping conditions.

  2020cited by this paper
• Tauopathy and Movement Disorders—Unveiling the Chameleons and Mimics

  2020cited by this paper
• Tau molecular diversity contributes to clinical heterogeneity in Alzheimer’s disease

  2020cited by this paper
• The structure and phase of tau: from monomer to amyloid filament

  2020cited by this paper

• Targeting dual specificity tyrosine-phosphorylation-regulated kinase 1A mitigates tauopathy and enhances recovery after repetitive head injury.

  2026cites this paper
• Extracellular tau oligomers exert neurocytotoxicity by triggering mitochondrial dysfunction

  2026cites this paper
• Sex-specific effects of acetylation on tauopathy in aging htau mice.

  2026cites this paper
• Experimental Models and Translational Strategies in Neuroprotective Drug Development with Emphasis on Alzheimer’s Disease

  2026cites this paper
• Tau Protein Aggregation Inhibitors—Therapeutic Strategy for Concurrent Tau and Amyloid Aggregation Inhibition

  2026cites this paper
• Implications of virus-induced stress granules in tauopathies

  2026cites this paper
• An Electrochemiluminescence Aptasensor Based on Luminescent‐Nanospheres Coupling With Reconfigurable Switchable System for Detection of Oligomeric A β

  2026cites this paper
• Heterotypic phase separation in aggregation: Driver or deterrent?

  2026cites this paper
• Novel strategies for targeting tau oligomers in neurodegenerative diseases

  2025cites this paper
• The Role of Inflammation in Neurodegenerative Diseases: Parkinson’s Disease, Alzheimer’s Disease, and Multiple Sclerosis

  2025cites this paper
• Tauopathies: Emerging discoveries on tau protein, with a special focus on Alzheimer's disease.

  2025cites this paper
• Tau protein and major depressive disorder: A meta-analysis of biomarker studies.

  2025cites this paper
• A High-Throughput ImmunoHistoFluorescence (IHF) Method for Sub-Nuclear Protein Analysis in Tissue

  2025cites this paper
• Rational Modulation of Liquid–Liquid Phase Separation Offers Novel Ways to Combat Tauopathies

  2025cites this paper
• Multiple Mechanisms and Therapeutic Strategies for the Involvement of AMPK in the Development of Alzheimer’s Disease

  2025cites this paper
• New Approaches to the Treatment of Alzheimer’s Disease

  2025cites this paper
• Tauopathies: Calmodulin Regulates Tau Hyperphosphorylation and Its Transformation into Disease-Specific Aggregates

  2025cites this paper
• Targeting Metal Imbalance and Oxidative Stress in Alzheimer’s Disease with Novel Multifunctional Compounds

  2025cites this paper
• Therapeutic Modalities Targeting Tau Protein in Alzheimer’s Disease

  2025cites this paper
• Disease-specific tau polymorphs define unique protein interaction networks across proteinopathies

  2025cites this paper
• Establishment and verification of reference intervals for Alzheimer's disease plasma biomarkers based on evaluation of pre‐analytical procedures: a multicenter study

  2025cites this paper
• Computational Insights into the Destabilization of Baicalein on the Tau Protofibrils Associated with Alzheimer' s Disease and Chronic Traumatic Encephalopathy.

  2025cites this paper
• Druggable Ensembles of Aβ and Tau: Intrinsically Disordered Proteins Biophysics, Liquid–Liquid Phase Separation and Multiscale Modeling for Alzheimer’s

  2025cites this paper
• Therapeutic Potentials of the Seaweed-Derived Compounds for Alzheimer’s Disease

  2025cites this paper
• Tau–Mitochondria Interactions in Neurodegeneration: Mechanisms and Therapeutic Potential

  2025cites this paper
• Targeting Liquid-Liquid Phase Separation and Autophagy in Alzheimer’s Disease: Insights into Molecular Mechanisms and Therapeutic Potential

  2025cites this paper
• Probing tau citrullination in Alzheimer’s disease brains and mouse models of tauopathy

  2025cites this paper
• APOE isoform‐associated tau oligomer polymorphs differ in synaptotoxicity and seeding activity

  2025cites this paper
• Catalytic Effect of Amyloid-β on Native Tau Aggregation at Physiologically Relevant Concentrations

  2025cites this paper
• Selective degradation of DAPK1 via a novel hydrophobic tagging attenuates tau pathology in Alzheimer's disease.

  2025cites this paper
• Tau post-translational modifications in Alzheimer's disease: insights into pathogenesis, therapeutic strategies, and diagnostic advances

  2025cites this paper
• Meroterpenoids from Terrestrial and Marine Fungi: Promising Agents for Neurodegenerative Disorders—An Updated Review

  2025cites this paper
• Advancing Alzheimer's Therapy: Computational strategies and treatment innovations

  2025cites this paper
• Identification of Depression Subtypes in Parkinson's Disease Patients via Structural MRI Whole‐Brain Radiomics: An Unsupervised Machine Learning Study

  2025cites this paper
• Fibrinogen-tau Aggregates Exacerbate Tau Pathology and Memory Deficits in Alzheimer’s Disease Model Mice

  2025cites this paper
• Cellular Prion Protein and Amyloid-β Oligomers in Alzheimer’s Disease—Are There Connections?

  2025cites this paper
• Intracellular anionic substances cause tau liquid-liquid phase separation.

  2025cites this paper
• α-synuclein and tau: interactions, cross-seeding, and the redefinition of synucleinopathies as complex proteinopathies

  2025cites this paper
• Pilot Study for Deciphering Post-Translational Modifications and Proteoforms of Tau Protein by Capillary Electrophoresis-Mass Spectrometry

  2024cites this paper
• Potential biofluid markers for cognitive impairment in Parkinson’s disease

  2024cites this paper
• Proteopathic seed amplification assays in easily accessible specimens for human synucleinopathies, tauopathies and prionopathies: a Scoping Review.

  2024cites this paper
• A coupled mathematical and numerical model for protein spreading and tissue atrophy, applied to Alzheimer's disease

  2024cites this paper
• Detecting the Undetectable: Advances in Methods for Identifying Small Tau Aggregates in Neurodegenerative Diseases

  2024cites this paper
• High‐molecular‐weight oligomer tau (HMWoTau) species are dramatically increased in Braak‐stage dependent manner in the frontal lobe of human brains, demonstrated by a novel oligomer Tau ELISA with a mouse monoclonal antibody (APNmAb005)

  2024cites this paper